伊替马唑 T32194

Product Introduction
Bioactivity


英文名: Irtemazole

描述: Irtemazole (R 60844) 是一种新型排尿酸物质，在治疗高尿酸血症和痛风方面很有价值。

体内活性: Irtemazole (12.5 to 50 mg; oral; 6 patients) caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.[2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/mL (190.74 mM)


关键字: Irtemazole

相关库: Bioactive Compounds Library Max | Bioactive Compound Library

伊替马唑 T32194信息由TargetMol中国为您提供，如您想了解更多关于伊替马唑 T32194报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途